Purdue Research Park-based Life Sciences Firm Receives $300,000 NIH Grant
News Nov 16, 2012
Tymora Analytical Operations LLC, a Purdue Research Park-based company, received the SBIR Phase I grant to optimize and strengthen its PolyMAC product. The technology promotes the discovery of new disease targets in laboratory settings. It is based on research by W. Andy Tao, associate professor in Purdue's Department of Biochemistry. The company licensed the technology through the Purdue Office of Technology Commercialization.
Anton Iliuk, president and chief technology officer, said PolyMAC could help determine whether a potential drug in development is focused on the intended disease targets. He described how the NIH funding will benefit Tymora Analytical Operations' efforts.
"Products currently available on the market typically see only the tip of the iceberg of a disease," he said. "PolyMAC technology allows a researcher to dive deeper into the complicated disease network to find the most optimal and promising treatment targets."
Iliuk said the company's focus is to strengthen efforts in university and industrial laboratories to find more effective, efficient drug treatment candidates for cancer, immunological and infectious illnesses, and diabetes.
Tymora Analytical Operations received a $150,000 SBIR Phase I grant from the NIH to develop an application for its pIMAGO platform earlier in 2012. It also received a $150,000 SBIR Phase I grant from the National Science Foundation in 2011, and $20,000 from the Purdue-administered Emerging Innovations Fund in 2012.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE